Vault-13

DEERFIELD MANAGEMENT COMPANY, L.P.

New York, NY · CIK 1009258 · 13F filing filed 2022-08-15

SEC-registered investment adviser since 2012 · limited partnership

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
New York, NY (main office)United States United Statesabout 86
Parsippany, NJUnited States United States3

US visa salary filings

Job titleFilingsMedianRange
AnalystNew York, NY 2 $140,000
Data EngineerNew York, NY 1 $210,000
Senior Director, Business IntelligenceNew York, NY 1 $195,000
Director, Business IntelligenceNew York, NY 1 $180,000
Market Research AssociateNew York, NY 1 $80,000

Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Deerfield Management Company, L.P..

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$4.7bn reported value +6.2% vs Q1 2022
126positions
38.7%in top 10
21 new 25 added 12 reduced 16 sold out vs Q1 2022

Options: 1 call positions ($102.0m notional), 0 put positions (— notional) – listed below, not included above.

This report includes the holdings of 1 other manager that shares the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 GLAUKOS CORP NOTE 2.750% 6/1 · principal GKOS 2.75 06.15.27 · principal GKOS 2.75 06.15.27 271,752,000 $324.5m6.84% 6.84% AddedPrincipal held: Q3 2021 108.0m, Q4 2021 204.7m, Q1 2022 269.9m, Q2 2022 271.8m +1.9m +1,855,000 0.7%
2 NUVALENT INC COM COM 19,341,024 $262.3m5.53% 5.53% UnchangedShares held: Q3 2021 19.3m, Q4 2021 19.3m, Q1 2022 19.3m, Q2 2022 19.3m
3 VIATRIS INC COM VTRS VTRS 20,673,700 $216.5m4.56% 4.56% UnchangedShares held: Q3 2021 18.8m, Q4 2021 20.8m, Q1 2022 20.7m, Q2 2022 20.7m
4 ADAPTHEALTH CORP COMMON STOCK AHCO AHCO 11,150,797 $201.2m4.24% 4.24% ReducedShares held: Q3 2021 8.1m, Q4 2021 10.2m, Q1 2022 11.7m, Q2 2022 11.2m -499.3k -499,275 -4.3%
5 NEUROCRINE BIOSCIENCES INC COM NBIX NBIX 2,012,714 $196.2m4.13% 4.13% AddedShares held: Q3 2021 1.1m, Q4 2021 1.4m, Q1 2022 1.7m, Q2 2022 2.0m +354.9k +354,914 21.4%
6 INVITAE CORP NOTE 2.000% 9/0 · principal NVTA 2 09.01.24 · principal NVTA 2 09.01.24 206,873,000 $163.0m3.43% 3.43% UnchangedPrincipal held: Q3 2021 163.4m, Q4 2021 163.4m, Q1 2022 206.9m, Q2 2022 206.9m
7 AERIE PHARMACEUTICALS INC NOTE 1.500%10/0 · principal AERI 1.5 10.01.24 · principal AERI 1.5 10.01.24 157,390,000 $133.0m2.80% 2.80% UnchangedPrincipal held: Q3 2021 157.4m, Q4 2021 157.4m, Q1 2022 157.4m, Q2 2022 157.4m
8 IONIS PHARMACEUTICALS INC NOTE 4/0 · principal IONS 0 04.01.26 · principal IONS 0 04.01.26 127,800,000 $117.0m2.46% 2.46% NewPrincipal held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 127.8m
9 NATERA INC NOTE 2.250% 5/0 · principal NTRA 2.25 05.01.27 · principal NTRA 2.25 05.01.27 90,638,000 $111.9m2.36% 2.36% UnchangedPrincipal held: Q3 2021 45.0m, Q4 2021 45.0m, Q1 2022 90.6m, Q2 2022 90.6m
10 SAREPTA THERAPEUTICS INC DBCV 1.500%11/1 SRPT 1.5 11.15.24 SRPT 1.5 11.15.24 88,657,000 $111.8m2.35% 2.35% UnchangedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 88.7m, Q2 2022 88.7m
11 ENVISTA HOLDINGS CORPORATION NOTE 2.375% 6/0 · principal NVST 2.375 06.01.25 · principal NVST 2.375 06.01.25 52,500,000 $100.4m2.11% 2.11% UnchangedPrincipal held: Q3 2021 52.5m, Q4 2021 52.5m, Q1 2022 52.5m, Q2 2022 52.5m
12 SILK RD MED INC COM SILK SILK 2,676,891 $97.4m2.05% 2.05% AddedShares held: Q3 2021 990.3k, Q4 2021 1.5m, Q1 2022 2.2m, Q2 2022 2.7m +523.2k +523,179 24.3%
13 TABULA RASA HEALTHCARE INC NOTE 1.750% 2/1 · principal TRHC 1.75 02.15.26 · principal TRHC 1.75 02.15.26 144,516,000 $97.2m2.05% 2.05% AddedPrincipal held: Q3 2021 45.0m, Q4 2021 97.8m, Q1 2022 107.8m, Q2 2022 144.5m +36.7m +36,700,000 34.0%
14 GILEAD SCIENCES INC COM GILD GILD 1,552,639 $96.0m2.02% 2.02% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 765.5k, Q2 2022 1.6m +787.1k +787,150 102.8%
15 NUVASIVE INC NOTE 1.000% 6/0 · principal GMED 1 06.01.23 · principal GMED 1 06.01.23 96,966,000 $93.6m1.97% 1.97% UnchangedPrincipal held: Q3 2021 97.0m, Q4 2021 97.0m, Q1 2022 97.0m, Q2 2022 97.0m
16 PACIRA BIOSCIENCES INC NOTE 0.750% 8/0 · principal PCRX 0.75 08.01.25 · principal PCRX 0.75 08.01.25 81,600,000 $85.0m1.79% 1.79% UnchangedPrincipal held: Q3 2021 81.6m, Q4 2021 81.6m, Q1 2022 81.6m, Q2 2022 81.6m
17 DECIPHERA PHARMACEUTICALS IN COM DCPH DCPH 6,250,964 $82.2m1.73% 1.73% AddedShares held: Q3 2021 815.0k, Q4 2021 5.6m, Q1 2022 5.6m, Q2 2022 6.3m +670.5k +670,508 12.0%
18 APELLIS PHARMACEUTICALS INC NOTE 3.500% 9/1 · principal APLS 3.5 09.15.26 · principal APLS 3.5 09.15.26 51,885,000 $76.5m1.61% 1.61% UnchangedPrincipal held: Q3 2021 28.8m, Q4 2021 28.8m, Q1 2022 51.9m, Q2 2022 51.9m
19 NUVASIVE INC NOTE 0.375% 3/1 · principal GMED 0.375 03.15.25 · principal GMED 0.375 03.15.25 80,000,000 $71.7m1.51% 1.51% UnchangedPrincipal held: Q3 2021 55.8m, Q4 2021 77.9m, Q1 2022 80.0m, Q2 2022 80.0m
20 INSMED INC NOTE 1.750% 1/1 · principal INSM 1.75 01.15.25 · principal INSM 1.75 01.15.25 75,000,000 $70.5m1.48% 1.48% UnchangedPrincipal held: Q3 2021 50.0m, Q4 2021 50.0m, Q1 2022 75.0m, Q2 2022 75.0m
21 IMMUNOGEN INC COM IMGN IMGN 15,020,490 $67.6m1.42% 1.42% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 3.5m, Q2 2022 15.0m +11.5m +11,549,815 332.8%
22 INSULET CORP NOTE 0.375% 9/0 · principal PODD 0.375 09.01.26 · principal PODD 0.375 09.01.26 57,581,000 $66.0m1.39% 1.39% UnchangedPrincipal held: Q3 2021 57.6m, Q4 2021 57.6m, Q1 2022 57.6m, Q2 2022 57.6m
23 MIRUM PHARMACEUTICALS INC COM MIRM MIRM 3,244,434 $63.1m1.33% 1.33% ReducedShares held: Q3 2021 3.3m, Q4 2021 3.3m, Q1 2022 3.3m, Q2 2022 3.2m -38.5k -38,478 -1.2%
24 DAY ONE BIOPHARMACEUTICALS I COM COM 3,512,123 $62.9m1.32% 1.32% AddedShares held: Q3 2021 1.7m, Q4 2021 2.2m, Q1 2022 2.1m, Q2 2022 3.5m +1.4m +1,425,674 68.3%
25 ACCOLADE INC NOTE 0.500% 4/0 · principal ACCD 0.5 04.01.26 · principal ACCD 0.5 04.01.26 92,624,000 $59.1m1.25% 1.25% NewPrincipal held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 92.6m
26 NEVRO CORP NOTE 2.750% 4/0 · principal NVRO 2.75 04.01.25 · principal NVRO 2.75 04.01.25 61,000,000 $57.7m1.22% 1.22% UnchangedPrincipal held: Q3 2021 26.0m, Q4 2021 61.0m, Q1 2022 61.0m, Q2 2022 61.0m
27 CAREMAX INC COM CL A COM CL A 15,861,090 $57.6m1.21% 1.21% UnchangedShares held: Q3 2021 16.8m, Q4 2021 16.8m, Q1 2022 15.9m, Q2 2022 15.9m
28 GUARDANT HEALTH INC NOTE 11/1 · principal GH 0 11.15.27 · principal GH 0 11.15.27 89,036,000 $56.7m1.19% 1.19% NewPrincipal held: Q3 2021 0, Q4 2021 8.0m, Q1 2022 0, Q2 2022 89.0m
29 INTERCEPT PHARMACEUTICALS IN NOTE 3.250% 7/0 · principal ICPT 3.25 07.01.23 · principal ICPT 3.25 07.01.23 57,791,000 $56.2m1.18% 1.18% UnchangedPrincipal held: Q3 2021 57.8m, Q4 2021 57.8m, Q1 2022 57.8m, Q2 2022 57.8m
30 COGENT BIOSCIENCES INC COM COGT COGT 5,876,805 $53.0m1.12% 1.12% AddedShares held: Q3 2021 1.6m, Q4 2021 1.6m, Q1 2022 1.6m, Q2 2022 5.9m +4.3m +4,275,805 267.1%
31 PULMONX CORP COM LUNG LUNG 3,465,901 $51.0m1.07% 1.07% ReducedShares held: Q3 2021 2.0m, Q4 2021 2.4m, Q1 2022 3.7m, Q2 2022 3.5m -229.4k -229,440 -6.2%
32 IVERIC BIO INC COM OPHT OPHT 5,214,000 $50.2m1.06% 1.06% AddedShares held: Q3 2021 4.9m, Q4 2021 4.8m, Q1 2022 4.9m, Q2 2022 5.2m +322.0k +322,004 6.6%
33 CENTENE CORP DEL COM CNC CNC 578,800 $49.0m1.03% 1.03% AddedShares held: Q3 2021 1.0m, Q4 2021 1.0m, Q1 2022 553.8k, Q2 2022 578.8k +25.0k +25,000 4.5%
34 OAK STR HEALTH INC NOTE 3/1 OSH 0 03.15.26 OSH 0 03.15.26 68,000,000 $48.6m1.02% 1.02% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 68.0m
35 KURA ONCOLOGY INC COM KURA KURA 2,627,000 $48.2m1.01% 1.01% ReducedShares held: Q3 2021 2.3m, Q4 2021 3.5m, Q1 2022 4.4m, Q2 2022 2.6m -1.8m -1,789,361 -40.5%
36 GLAUKOS CORP COM GKOS GKOS 1,039,514 $47.2m0.99% 0.99% AddedShares held: Q3 2021 619.0k, Q4 2021 1.2m, Q1 2022 369.5k, Q2 2022 1.0m +670.0k +670,000 181.3%
37 MOLINA HEALTHCARE INC COM MOH MOH 167,000 $46.7m0.98% 0.98% AddedShares held: Q3 2021 231.8k, Q4 2021 135.0k, Q1 2022 135.0k, Q2 2022 167.0k +32.0k +32,011 23.7%
38 CYTOKINETICS INC COM NEW CYTK CYTK 1,160,315 $45.6m0.96% 0.96% AddedShares held: Q3 2021 1.5m, Q4 2021 809.0k, Q1 2022 952.7k, Q2 2022 1.2m +207.6k +207,612 21.8%
39 MERUS N V COM MRUS MRUS 1,985,924 $45.0m0.95% 0.95% AddedShares held: Q3 2021 0, Q4 2021 437.0k, Q1 2022 437.0k, Q2 2022 2.0m +1.5m +1,548,924 354.4%
40 DYNAVAX TECHNOLOGIES CORP NOTE 2.500% 5/1 · principal DVAX 2.5 05.15.26 · principal DVAX 2.5 05.15.26 30,000,000 $44.7m0.94% 0.94% NewPrincipal held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 30.0m
41 LIVONGO HEALTH INC NOTE 0.875% 6/0 · principal TDOC 0.875 06.01.25 · principal TDOC 0.875 06.01.25 50,000,000 $42.4m0.89% 0.89% NewPrincipal held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 50.0m
42 EVOLUS INC COM EOLS EOLS 3,632,751 $42.1m0.89% 0.89% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 1.2m, Q2 2022 3.6m +2.4m +2,403,517 195.5%
43 1LIFE HEALTHCARE INC NOTE 3.000% 6/1 · principal ONEM 3 06.15.25 · principal ONEM 3 06.15.25 48,599,000 $40.2m0.85% 0.85% AddedPrincipal held: Q3 2021 0, Q4 2021 0, Q1 2022 40.0m, Q2 2022 48.6m +8.6m +8,599,000 21.5%
44 BROOKDALE SR LIVING INC COM BKD BKD 8,592,461 $39.0m0.82% 0.82% AddedShares held: Q3 2021 5.3m, Q4 2021 4.3m, Q1 2022 5.4m, Q2 2022 8.6m +3.2m +3,213,461 59.7%
45 AERIE PHARMACEUTICALS INC COM AERI AERI 4,695,020 $35.2m0.74% 0.74% UnchangedShares held: Q3 2021 3.0m, Q4 2021 4.7m, Q1 2022 4.7m, Q2 2022 4.7m
46 PTC THERAPEUTICS INC NOTE 1.500% 9/1 · principal PTCT 1.5 09.15.26 · principal PTCT 1.5 09.15.26 32,000,000 $33.4m0.70% 0.70% NewPrincipal held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 32.0m
47 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 3,933,137 $31.3m0.66% 0.66% UnchangedShares held: Q3 2021 3.9m, Q4 2021 3.9m, Q1 2022 3.9m, Q2 2022 3.9m
48 HILLEVAX INC COM COM 2,617,948 $28.6m0.60% 0.60% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 2.6m
49 PHARVARIS N V COM PHVS PHVS 1,190,343 $26.3m0.55% 0.55% ReducedShares held: Q3 2021 1.6m, Q4 2021 1.6m, Q1 2022 1.6m, Q2 2022 1.2m -386.7k -386,735 -24.5%
50 PTC THERAPEUTICS INC NOTE 3.000% 8/1 · principal PTCT 3 08.15.22 · principal PTCT 3 08.15.22 25,417,000 $25.5m0.54% 0.54% AddedPrincipal held: Q3 2021 14.5m, Q4 2021 14.5m, Q1 2022 14.5m, Q2 2022 25.4m +10.9m +10,890,000 75.0%
51 HORIZON THERAPEUTICS PUB L SHS HZNP HZNP 313,000 $25.0m0.53% 0.53% ReducedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 465.0k, Q2 2022 313.0k -152.0k -152,000 -32.7%
52 NOVAVAX INC NOTE 3.750% 2/0 · principal NVAX 3.75 02.01.23 · principal NVAX 3.75 02.01.23 25,000,000 $24.9m0.52% 0.52% UnchangedPrincipal held: Q3 2021 25.0m, Q4 2021 25.0m, Q1 2022 25.0m, Q2 2022 25.0m
53 SINGULAR GENOMICS SYSTEMS IN COM COM 6,336,330 $24.2m0.51% 0.51% ReducedShares held: Q3 2021 9.1m, Q4 2021 9.1m, Q1 2022 6.6m, Q2 2022 6.3m -275.7k -275,689 -4.2%
54 SEMA4 HOLDINGS CORP COM CL A SMFR SMFR 18,848,488 $23.7m0.50% 0.50% AddedShares held: Q3 2021 13.8m, Q4 2021 14.0m, Q1 2022 13.8m, Q2 2022 18.8m +5.0m +5,000,000 36.1%
55 BELLUS HEALTH INC NEW COM NEW BLU BLU 2,473,000 $22.9m0.48% 0.48% ReducedShares held: Q3 2021 0, Q4 2021 2.4m, Q1 2022 3.7m, Q2 2022 2.5m -1.2m -1,199,808 -32.7%
56 ORGANOGENESIS HLDGS INC COM ORGO ORGO 4,447,740 $21.7m0.46% 0.46% ReducedShares held: Q3 2021 7.5m, Q4 2021 8.5m, Q1 2022 8.5m, Q2 2022 4.4m -4.0m -4,009,136 -47.4%
57 PHREESIA INC COM PHR PHR 857,115 $21.4m0.45% 0.45% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 857.1k
58 SYNDAX PHARMACEUTICALS INC COM SNDX SNDX 1,111,111 $21.4m0.45% 0.45% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 1.1m
59 AMEDISYS INC COM AMED AMED 199,000 $20.9m0.44% 0.44% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 199.0k
60 TARSUS PHARMACEUTICALS INC COM TARS TARS 1,324,214 $19.3m0.41% 0.41% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 1.3m
61 INSMED INC COM PAR $.01 INSM INSM 960,484 $18.9m0.40% 0.40% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 304.6k, Q2 2022 960.5k +655.9k +655,912 215.4%
62 XERIS PHARMACEUTICALS INC NOTE 5.000% 7/1 · principal XERS 5 07.15.25 · principal XERS 5 07.15.25 18,000,000 $17.6m0.37% 0.37% UnchangedPrincipal held: Q3 2021 18.0m, Q4 2021 18.0m, Q1 2022 18.0m, Q2 2022 18.0m
63 REVOLUTION MEDICINES INC COM RVMD RVMD 891,587 $17.4m0.37% 0.37% UnchangedShares held: Q3 2021 1.6m, Q4 2021 891.6k, Q1 2022 891.6k, Q2 2022 891.6k
64 THE ONCOLOGY INSTITUTE INC COM STLN STLN 3,383,099 $17.1m0.36% 0.36% AddedShares held: Q3 2021 0, Q4 2021 3.3m, Q1 2022 3.3m, Q2 2022 3.4m +87.0k +86,992 2.6%
65 PACIRA BIOSCIENCES INC COM PCRX PCRX 292,000 $17.0m0.36% 0.36% NewShares held: Q3 2021 967.2k, Q4 2021 596.3k, Q1 2022 0, Q2 2022 292.0k
66 ALPHATEC HLDGS INC COM NEW ATEC ATEC 2,420,547 $15.8m0.33% 0.33% ReducedShares held: Q3 2021 3.6m, Q4 2021 3.6m, Q1 2022 3.6m, Q2 2022 2.4m -1.2m -1,174,282 -32.7%
67 ANAPTYSBIO INC COM ANAB ANAB 772,000 $15.7m0.33% 0.33% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 772.0k
68 DA32 LIFE SCNCE TEC ACQSTN C CLASS A COM CLASS A COM 1,600,000 $15.5m0.33% 0.33% UnchangedShares held: Q3 2021 1.6m, Q4 2021 1.6m, Q1 2022 1.6m, Q2 2022 1.6m
69 HEALTH CATALYST INC NOTE 2.500% 4/1 · principal HCAT 2.5 04.15.25 · principal HCAT 2.5 04.15.25 15,000,000 $13.5m0.28% 0.28% UnchangedPrincipal held: Q3 2021 15.0m, Q4 2021 15.0m, Q1 2022 15.0m, Q2 2022 15.0m
70 INOZYME PHARMA INC COM COM 2,696,372 $12.9m0.27% 0.27% AddedShares held: Q3 2021 2.3m, Q4 2021 2.3m, Q1 2022 2.3m, Q2 2022 2.7m +351.6k +351,586 15.0%
71 PROFOUND MED CORP COM NEW PROF PROF 1,713,797 $12.5m0.26% 0.26% UnchangedShares held: Q3 2021 1.3m, Q4 2021 1.7m, Q1 2022 1.7m, Q2 2022 1.7m
72 KEZAR LIFE SCIENCES INC COM COM 1,419,000 $11.7m0.25% 0.25% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 1.4m
73 LARIMAR THERAPEUTICS INC COM LRMR LRMR 5,830,249 $11.4m0.24% 0.24% UnchangedShares held: Q3 2021 5.8m, Q4 2021 5.8m, Q1 2022 5.8m, Q2 2022 5.8m
74 TG THERAPEUTICS INC COM TGTX TGTX 2,677,500 $11.4m0.24% 0.24% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 2.7m
75 ALECTOR INC COM ALEC ALEC 1,055,192 $10.7m0.23% 0.23% UnchangedShares held: Q3 2021 1.1m, Q4 2021 1.1m, Q1 2022 1.1m, Q2 2022 1.1m
76 FOGHORN THERAPEUTICS INC COM FHTX FHTX 777,525 $10.6m0.22% 0.22% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 238.9k, Q2 2022 777.5k +538.7k +538,660 225.5%
77 EUCRATES BIOMEDICAL ACQU COR SHS SHS 999,999 $9.9m0.21% 0.21% UnchangedShares held: Q3 2021 0, Q4 2021 1,000.0k, Q1 2022 1,000.0k, Q2 2022 1,000.0k
78 SARISSA CAPITAL ACQUISITN CO CL A CL A 999,999 $9.9m0.21% 0.21% UnchangedShares held: Q3 2021 0, Q4 2021 1,000.0k, Q1 2022 1,000.0k, Q2 2022 1,000.0k
79 MEDTECH ACQUISITION CORP COM CL A COM CL A 999,999 $9.8m0.21% 0.21% UnchangedShares held: Q3 2021 1,000.0k, Q4 2021 1,000.0k, Q1 2022 1,000.0k, Q2 2022 1,000.0k
80 SENIOR CONNECT ACQUISITN COR COM CL A COM CL A 1,000,000 $9.8m0.21% 0.21% UnchangedShares held: Q3 2021 1.0m, Q4 2021 1.0m, Q1 2022 1.0m, Q2 2022 1.0m
81 REVOLUTION HEALTHCAR AQ CORP CLASS A COM CLASS A COM 1,000,000 $9.8m0.21% 0.21% UnchangedShares held: Q3 2021 1.0m, Q4 2021 1.0m, Q1 2022 1.0m, Q2 2022 1.0m
82 PEPGEN INC COM PEPG PEPG 953,626 $9.5m0.20% 0.20% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 953.6k
83 TURMERIC ACQUISITION CORP CL A CL A 750,000 $7.4m0.16% 0.16% UnchangedShares held: Q3 2021 0, Q4 2021 750.0k, Q1 2022 750.0k, Q2 2022 750.0k
84 NKARTA INC COM NKTX NKTX 600,000 $7.4m0.16% 0.16% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 600.0k
85 IGNYTE ACQUISITION CORP COM COM 725,000 $7.1m0.15% 0.15% UnchangedShares held: Q3 2021 725.0k, Q4 2021 725.0k, Q1 2022 725.0k, Q2 2022 725.0k
86 APOLLO ENDOSURGERY INC COM COM 1,750,000 $6.4m0.13% 0.13% UnchangedShares held: Q3 2021 0, Q4 2021 1.8m, Q1 2022 1.8m, Q2 2022 1.8m
87 XILIO THERAPEUTICS INC COM COM 2,078,692 $6.1m0.13% 0.13% UnchangedShares held: Q3 2021 0, Q4 2021 2.2m, Q1 2022 2.1m, Q2 2022 2.1m
88 OUTSET MED INC COM OM OM 400,622 $6.0m0.13% 0.13% UnchangedShares held: Q3 2021 400.6k, Q4 2021 400.6k, Q1 2022 400.6k, Q2 2022 400.6k
89 BENEFITFOCUS INC NOTE 1.250%12/1 · principal BNFT 1.25 12.15.23 · principal BNFT 1.25 12.15.23 6,500,000 $5.9m0.12% 0.12% NewPrincipal held: Q3 2021 6.5m, Q4 2021 0, Q1 2022 0, Q2 2022 6.5m
90 GRAYBUG VISION INC COM SHS COM SHS 5,281,713 $5.8m0.12% 0.12% UnchangedShares held: Q3 2021 5.3m, Q4 2021 5.3m, Q1 2022 5.3m, Q2 2022 5.3m
91 AN2 THERAPEUTICS INC COM ANTX ANTX 716,538 $5.6m0.12% 0.12% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 584.1k, Q2 2022 716.5k +132.4k +132,402 22.7%
92 NEOGENOMICS INC NOTE 1.250% 5/0 · principal NEO 1.25 05.01.25 · principal NEO 1.25 05.01.25 6,500,000 $5.4m0.11% 0.11% NewPrincipal held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 6.5m
93 ORION ACQUISITION CORP COM CL A COM CL A 500,000 $4.9m0.10% 0.10% UnchangedShares held: Q3 2021 500.0k, Q4 2021 500.0k, Q1 2022 500.0k, Q2 2022 500.0k
94 NYXOAH S A SHS NYXH NYXH 455,262 $4.2m0.09% 0.09% UnchangedShares held: Q3 2021 300.8k, Q4 2021 455.3k, Q1 2022 455.3k, Q2 2022 455.3k
95 ORCHARD THERAPEUTICS PLC ADS ORTX ORTX 6,949,416 $4.1m0.09% 0.09% UnchangedShares held: Q3 2021 6.9m, Q4 2021 6.9m, Q1 2022 6.9m, Q2 2022 6.9m
96 ONCORUS INC COM COM 3,148,977 $4.0m0.08% 0.08% UnchangedShares held: Q3 2021 3.1m, Q4 2021 3.1m, Q1 2022 3.1m, Q2 2022 3.1m
97 WEREWOLF THERAPEUTICS INC COM HOWL HOWL 958,125 $3.9m0.08% 0.08% UnchangedShares held: Q3 2021 1.8m, Q4 2021 958.1k, Q1 2022 958.1k, Q2 2022 958.1k
98 QUANTUM SI INC COM CL A QSI QSI 1,400,000 $3.2m0.07% 0.07% UnchangedShares held: Q3 2021 1.4m, Q4 2021 1.4m, Q1 2022 1.4m, Q2 2022 1.4m
99 KINNATE BIOPHARMA INC COM KNTE KNTE 250,000 $3.2m0.07% 0.07% ReducedShares held: Q3 2021 1.0m, Q4 2021 985.6k, Q1 2022 985.6k, Q2 2022 250.0k -735.6k -735,568 -74.6%
100 ACUTUS MED INC COM AFIB AFIB 2,648,386 $3.0m0.06% 0.06% UnchangedShares held: Q3 2021 2.6m, Q4 2021 2.6m, Q1 2022 2.6m, Q2 2022 2.6m

Sold out since Q1 2022

SecurityTickerShares held beforeValue then
BRIDGEBIO PHARMA INC BBIO 2.5 03.15.27 BBIO 2.5 03.15.27 80,000,000 $47.4m80.0m shares
MIRATI THERAPEUTICS INC MRTX MRTX 270,000 $22.2m270.0k shares
GOODRX HLDGS INC GDRX GDRX 979,106 $18.9m979.1k shares
NUVATION BIO INC NUVB NUVB 3,577,233 $18.8m3.6m shares
BIOCRYST PHARMACEUTICALS INC BCRX BCRX 1,012,000 $16.5m1.0m shares
OAK STR HEALTH INC OSH 0 03.15.26 OSH 0 03.15.26 18,000,000 $14.3m18.0m shares
SPRINGWORKS THERAPEUTICS INC SWTX SWTX 249,988 $14.1m250.0k shares
KALVISTA PHARMACEUTICALS INC KALV KALV 830,472 $12.2m830.5k shares
TERNS PHARMACEUTICALS INC 2,345,959 $7.0m2.3m shares
BENEFITFOCUS INC BNFT 1.25 12.15.23 BNFT 1.25 12.15.23 6,500,000 $6.3m6.5m shares
VINCERX PHARMA INC 1,379,310 $5.5m1.4m shares
CULLINAN THERAPEUTICS INC CGEM CGEM 375,585 $3.9m375.6k shares
NEOGENOMICS INC NEO 0.25 01.15.28 NEO 0.25 01.15.28 2,500,000 $1.7m2.5m shares
AMERICAN WELL CORP 391,115 $1.6m391.1k shares
BIOATLA INC BCAB BCAB 289,002 $1.4m289.0k shares
PMV PHARMACEUTICALS INC PMVP PMVP 470 $10.0k470 shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
BIOGEN INC BIIB · Call BIIBCall 500,000 $102.0m500.0k shares New

Trades reported as a company insider in Q2 2022

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2022-06-06 MIRUM PHARMACEUTICALS INC 10% owner · Through Deerfield Private Design Fund IV, L.P. MIRM Sold 20,212 $505.5k20.2k shares -1%
2022-06-06 MIRUM PHARMACEUTICALS INC 10% owner · Through Deerfield Healthcare Innovations Fund, L.P. MIRM Sold 18,266 $456.8k18.3k shares -1%
2022-05-10 PEPGEN INC 10% owner · Through Deerfield Partners, L.P. PEPG Bought 208,333 $2.5m208.3k shares +78%
2022-05-10 PEPGEN INC 10% owner · Through Deerfield Private Design Fund V, L.P. PEPG Bought 208,333 $2.5m208.3k shares +78%